Luminex, Austin, Texas, has received FDA emergency use authorization (EUA) for its NxTag CoV extended panel. The multiplex test is intended for the detection of the SARS-CoV-2 virus. High-complexity molecular laboratories can now use the NxTag test on Luminex’s Magpix system to rapidly detect the virus that causes covid-19 for up to 96 patients in approximately 4 hours.
The NxTag CoV extended panel is a high-throughput, scalable, cost-effective option for detecting SARS-CoV-2. To provide a more complete picture of a patient’s respiratory health, the NxTag CoV extended panel can also be run in parallel with the NxTag respiratory pathogen panel. Luminex has expanded its manufacturing capacity to produce up to 300,000 NxTag tests per month, with the majority of that capacity focused on SARS-CoV-2.
“We are partnering with our customers at clinical laboratories to address the global pandemic, providing fast, reliable, scalable, multiplexed tests that can help stem the spread of covid-19 disease, while also ensuring that our tests are cost-effective,” says Nachum ‘Homi’ Shamir, president and chief executive officer of Luminex. “While there are many companies providing tests that can detect the SARS-CoV-2 strain, to our knowledge Luminex is the only company providing tests that can detect and differentiate between SARS-CoV-2 and the other common respiratory infections, while keeping price below government reimbursement levels to make testing more affordable for our customers and the healthcare system.”
For more information, visit Luminex.